Researchers design drug-carrying nanoparticles that can be taken orally
Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer. However, the particles have to be injected into patients, which has limited their usefulness so far.
Now, researchers from MIT and Brigham and Women’s Hospital (BWH) have developed a new type of nanoparticle that can be delivered orally and absorbed through the digestive tract, allowing patients to simply take a pill instead of receiving injections.
In a paper appearing in the Nov. 27 online edition of Science Translational Medicine, the researchers used the particles to demonstrate oral delivery of insulin in mice, but they say the particles could be used to carry any kind of drug that can be encapsulated in a nanoparticle. The new nanoparticles are coated with antibodies that act as a key to unlock receptors found on the surfaces of cells that line the intestine, allowing the nanoparticles to break through the intestinal walls and enter the bloodstream.
This type of drug delivery could be especially useful in developing new treatments for conditions such as high cholesterol or arthritis. Patients with those diseases would be much more likely to take pills regularly than to make frequent visits to a doctor’s office to receive nanoparticle injections, say the researchers.
“If you were a patient and you had a choice, there’s just no question: Patients would always prefer drugs they can take orally,” says Robert Langer, the David H. Koch Institute Professor at MIT, a member of MIT’s Koch Institute for Integrative Cancer Research, and an author of the Science Translational Medicine paper.
Lead authors of the paper are former MIT grad student Eric Pridgen and former BWH postdoc Frank Alexis, and the senior author is Omid Farokhzad, director of the Laboratory of Nanomedicine and Biomaterials at BWH. Other authors are Timothy Kuo, a gastroenterologist at BWH; Etgar Levy-Nissenbaum, a former BWH postdoc; Rohit Karnik, an MIT associate professor of mechanical engineering; and Richard Blumberg, co-director of BWH’s Biomedical Research Institute.
No more injections
Several types of nanoparticles carrying chemotherapy drugs or short interfering RNA, which can turn off selected genes, are now in clinical trials to treat cancer and other diseases. These particles exploit the fact that tumors and other diseased tissues are surrounded by leaky blood vessels. After the particles are intravenously injected into patients, they seep through those leaky vessels and release their payload at the tumor site.
For nanoparticles to be taken orally, they need to be able to get through the intestinal lining, which is made of a layer of epithelial cells that join together to form impenetrable barriers called tight junctions.
“The key challenge is how to make a nanoparticle get through this barrier of cells. Whenever cells want to form a barrier, they make these attachments from cell to cell, analogous to a brick wall where the bricks are the cells and the mortar is the attachments, and nothing can penetrate that wall,” Farokhzad says.
Researchers have previously tried to break through this wall by temporarily disrupting the tight junctions, allowing drugs through. However, this approach can have unwanted side effects because when the barriers are broken, harmful bacteria can also get through.
To build nanoparticles that can selectively break through the barrier, the researchers took advantage of previous work that revealed how babies absorb antibodies from their mothers’ milk, boosting their own immune defenses. Those antibodies grab onto a cell surface receptor called the FcRN, granting them access through the cells of the intestinal lining into adjacent blood vessels.
The researchers coated their nanoparticles with Fc proteins — the part of the antibody that binds to the FcRN receptor, which is also found in adult intestinal cells. The nanoparticles, made of a biocompatible polymer called PLA-PEG, can carry a large drug payload, such as insulin, in their core.
After the particles are ingested, the Fc proteins grab on to the FcRN in the intestinal lining and gain entry, bringing the entire nanoparticle along with them.
“It illustrates a very general concept where we can use these receptors to traffic nanoparticles that could contain pretty much anything. Any molecule that has difficulty crossing the barrier could be loaded in the nanoparticle and trafficked across,” Karnik says.
The researchers’ discovery of how this type of particle can penetrate cells is a key step to achieving oral nanoparticle delivery, says Edith Mathiowitz, a professor of molecular pharmacology, physiology, and biotechnology at Brown University.
The Latest Google Headlines on:
Nanoparticle drug delivery
The Latest Bing News on:
Nanoparticle drug delivery
- Cleveland Clinic’s nanoparticle-delivered COVID-19 vaccineon March 6, 2021 at 4:14 am
The vaccine candidate developed at the Cleveland Clinic's Global Center for Pathogen Research & Human Health shows promise in preclinical studies.
- Synthesis and design of Ag–Fe bimetallic nanoparticles as antimicrobial synergistic combination therapies against clinically relevant pathogenson March 5, 2021 at 5:25 am
In recent years, metallo-pharmaceutics and metallic nanoparticles have been proposed as potential alternative antimicrobials due to their broad-spectrum antimicrobial properties. Moreover, recent ...
- Nanoparticle COVID-19 vaccine shows promise in pre-clinical trialson March 2, 2021 at 6:47 pm
A new nanoparticle-based vaccine has demonstrated success in ferret models of COVID-19, inducing strong neutralising antibodies.
- Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studieson March 2, 2021 at 9:56 am
Researchers from Cleveland Clinic's Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong ...
- New nanoparticle-delivered COVID-19 vaccine candidate shows efficacy in ferret modelon March 2, 2021 at 8:55 am
Researchers from Cleveland Clinic's Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong ...
- Demand For Nanoparticles In Medicine Drives Growth Of The Nanosilica Industryon February 28, 2021 at 6:58 pm
Increased demand for nanoparticles in the medical industry contributed to the growth of the nano-silica market. Nanoparticles are presently being engaged as a tool to explore the ...
- Fabrication of anionic dextran-coated micelles for aptamer targeted delivery of camptothecin and survivin-shRNA to colon adenocarcinomaon February 25, 2021 at 7:01 am
In this study, we synthesized PLA-PEI micelles which was co-loaded with an anticancer drug, camptothecin (CPT), and survivin-shRNA (sur-shRNA). The hydrophobic CPT was encapsulated in the core of the ...
- VIDEO: On the Line: Watching Nanoparticles Get in Shapeon February 25, 2021 at 12:07 am
Berkeley Lab scientists have captured real-time, high-resolution videos of nanoparticles forming liquid structures for use in medicine and cosmetics.
- On the line: Watching nanoparticles get in shapeon February 25, 2021 at 12:05 am
Liquid structures—liquid droplets that maintain a specific shape—are useful for a variety of applications, from food processing to cosmetics, medicine, and even petroleum extraction, but researchers ...
- Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buyon February 23, 2021 at 5:47 pm
Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. GuideTx ...
The Latest Google Headlines on:
Oral nanoparticle delivery
The Latest Bing News on:
Oral nanoparticle delivery
- N4 Pharma falls after updateon February 24, 2021 at 2:45 am
The company, which is developing a delivery system for cancer and vaccine treatments using a silica nanoparticle delivery ... to explore the potential for oral delivery of vaccines.
- Additional Positive Interim Results from Nanoform’s Clinical Studyon February 24, 2021 at 12:10 am
This set of human data supports Nanoform’s claim that nanoparticles can enable faster dissolution rate, more rapid absorption, improve drug delivery performance, and ultimately generate patient ...
- Additional Positive Interim Results from Nanoform's Clinical Study | Morningstaron February 23, 2021 at 11:28 pm
Tax Planning Personal Finance Save for College Save for Retirement Invest in Retirement Research Mutual Funds Stocks ETFs Bonds Best Investments ...
- Additional Positive Interim Results from Nanoform's Clinical Studyon February 23, 2021 at 10:41 pm
HELSINKI, Feb. 24, 2021 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company ... PK profile of piroxicam following administration of nanoformed oral immediate ...
- Additional Positive Interim Results from Nanoform's Clinical Studyon February 23, 2021 at 10:32 pm
This was supported by the study, where the 20 mg CESS ® nanoformed oral piroxicam ... that nanoparticles can enable faster dissolution rate, more rapid absorption, improve drug delivery ...
- Additional Positive Interim Results from Nanoform's Clinical Studyon February 23, 2021 at 10:24 pm
This set of human data supports Nanoform's claim that nanoparticles can enable faster dissolution rate, more rapid absorption, improve drug delivery performance, and ultimately generate patient ...
- Items Tagged with 'LNP'on February 22, 2021 at 4:00 pm
Gene therapy developer Beam Therapeutics Inc. has acquired drug delivery specialist Guide Therapeutics Inc ... Evans told BioWorld the company is striving to build. Guide's lipid nanoparticle (LNP) ...
- Items Tagged with 'lipid nanoparticle'on February 22, 2021 at 4:00 pm
Gene therapy developer Beam Therapeutics Inc. has acquired drug delivery specialist Guide Therapeutics Inc ... Evans told BioWorld the company is striving to build. Guide's lipid nanoparticle (LNP) ...